Appetite Regulation and Mycoprotein

NCT ID: NCT02053025

Last Updated: 2019-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of eating various levels of mycoprotein (Quorn) on feelings of appetite, energy intake and levels of gut hormones in overweight volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Owing to its relatively high protein and fibre content, mycoprotein presents an attractive food product to improve appetite regulation and postprandial glycaemic and insulin responses in overweight and obese individuals at risk of developing T2DM

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Appetite Energy Intake

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mycoprotein

3 levels of mycoprotein will be consumed

Group Type ACTIVE_COMPARATOR

mycoprotein

Intervention Type DIETARY_SUPPLEMENT

control protein

3 levels of a control protein will be consumed

Group Type ACTIVE_COMPARATOR

control protein

Intervention Type DIETARY_SUPPLEMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mycoprotein

Intervention Type DIETARY_SUPPLEMENT

control protein

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females between the ages of 18 and 65
* body mass index (BMI) 25-32kg/m2
* Weight stable over the past 6 months
* No known major illness or eating disorder nor on any medication that may impact on appetite or hormone levels.
* No paracetamol or other analgesic in the previous 48 hours
* A score of \<2.5 in the Dutch Eating Behaviour Questionnaire (DEBQ)
* A score of \<2 in the SCOFF questionnaire

Exclusion Criteria

* Persons outside the age and BMI ranges stated above
* Pregnant and lactating women
* Weight variation of greater than 5% in the last 6 months
* Any diagnosed major illness
* Any paracetamol or analgesic intake in the last 48 hours
* Diagnosed eating disorder
* Allergy to mycoprotein or mushrooms
* Regular consumption of Quorn products
* Dislike of any of the test foods or drinks
* A score of \>2.5 in the Dutch Eating Behaviour questionnaire
* A score of 2 or more in the SCOFF questionaire
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Imperial College London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gary Frost

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Imperial College NIHR CRF

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Bottin JH, Swann JR, Cropp E, Chambers ES, Ford HE, Ghatei MA, Frost GS. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial. Br J Nutr. 2016 Jul;116(2):360-74. doi: 10.1017/S0007114516001872. Epub 2016 May 20.

Reference Type RESULT
PMID: 27198187 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRO1332

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Breakfast and Metabolism in Men
NCT03399812 COMPLETED NA
Digestibility of Fermotein™
NCT04819789 COMPLETED NA